Commercial Lines
Another Deadlocked Jury in a J&J Talc Cancer Trial
Jurors weighing claims that Johnson & Johnson's iconic baby powder is laced with cancer-causing asbestos failed in a second case in two weeks to reach a verdict, resulting in another mistrial. ...
RenaissanceRe Non-Committal About Exploring ‘Strategic Alternatives’
A ReinaissanceRe shareholder's call for the company to explore a possible sale is drawing a non-committal response from management. TimesSquare Capital Management, an institutional management firm ...
Are Current Climate Change Mitigation Targets Feasible? We’ll Find Out on Oct. 8
The world's leading climate scientists this week are preparing the final version of a cornerstone United Nations report to assess whether global temperatures can be kept in check this century to ...
Aspen Founder, CEO O’Kane to Depart in 2019; Brit Chairman Cloutier to Replace Him
Aspen Insurance Holdings Group Chief Executive Officer Chris O'Kane plans to step down in the 2019 first half, after investment manager Apollo Global Management LLC closes its $2.6 billion deal to ...
Credit Karma Jumps Into Insurance With Debut of Auto Policy Service
Financial technology startup Credit Karma said on Tuesday it is expanding into insurance through a new service that makes it easier for users to find cheaper auto insurance policies. The tool ...
UK’s Boris Johnson Blasts PM’s Brexit Plan as ‘Not Democracy’
Boris Johnson won cheers at the U.K. Conservative Party's annual conference with an attack on Theresa May's Brexit plan, but stopped short of calling for her to be removed as prime minister. While ...
UK VC Fund Focused on Insurance Makes First Two InsurTech Investments
Eos Venture Partners' strategic InsurTech fund has made its first two investments. The UK-based specialist venture capital fund, working through its debut EVP 1 fund, committed early financing to ...
AmTrust Shareholder Wants Regulator Rejection of $2.95B Privatization Plan or Higher Price
One of AmTrust Financial Services' shareholders is lobbying state regulators to oppose the insurer's move to go private. "Make no mistake, privatization is bad for investors, bad for brokers, bad for ...